TopoTarget A/S has appointed ABG Sundal Collier Holding ASA to review and advice on the execution of its strategic options. TopoTarget aims to maximize the value for its shareholders and hence decided to review strategic options. The options may include partnering of belinostat outside the territory of Spectrum Pharmaceuticals, Inc., a merger with an industrial partner, or a sale of TopoTarget.

The Board of Directors and Executive Management of TopoTarget have decided to change the structure and size of the Executive Management Team to reflect the current scope of the company's activities and prepare for the outcome of the strategic review.